What is HC Wainwright's Estimate for MAZE Q2 Earnings?

Key Points

• HC Wainwright estimates Maze Therapeutics will report a Q2 2027 loss of $0.65 per share, with the same EPS loss forecast for Q3 2027. The full-year consensus estimate is a loss of $2.72 per share.
• HC Wainwright maintains a Buy rating and a $110 price target, well above the analyst consensus target of $63.40; overall, Maze carries an average “Buy” rating.
• Maze shares opened at $26.43, while the company most recently reported a quarterly loss of $0.76 per share, in line with consensus estimates.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2027 EPS estimates for Maze Therapeutics in a research note issued on Monday, October 5th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings of ($0.65) per share for the quarter. HC Wainwright has a "Buy" rating and a $110.00 price objective on the stock. The consensus estimate for Maze Therapeutics' current full-year earnings is ($2.72) per share. HC Wainwright also issued estimates for Maze Therapeutics' Q3 2027 earnings at ($0.65) EPS.

MAZE has been the topic of several other reports. Wedbush restated an "outperform" rating and issued a $48.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. BTIG Research reissued a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Finally, Citigroup started coverage on Maze Therapeutics in a research note on Wednesday, September 23rd. They issued a "buy" rating and a $50.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $63.40.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $26.43 on Tuesday. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company has a market capitalization of $1.47 billion, a P/E ratio of -10.49 and a beta of 2.16. The company has a fifty day moving average of $26.93 and a 200 day moving average of $27.89.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.76).

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics in the 2nd quarter worth approximately $48,000. Royal Bank of Canada lifted its position in Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company's stock worth $61,000 after buying an additional 1,383 shares during the last quarter. Quantbot Technologies LP bought a new stake in Maze Therapeutics in the second quarter worth $80,000. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics during the fourth quarter worth $145,000. Finally, Persistent Asset Partners Ltd purchased a new position in Maze Therapeutics during the second quarter worth $200,000.

Insider Buying and Selling at Maze Therapeutics

In related news, CMO Harold Bernstein sold 16,142 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer owned 16,142 shares of the company's stock, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the completion of the transaction, the chief executive officer owned 18,151 shares of the company's stock, valued at approximately $477,189.79. This represents a 65.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 192,991 shares of company stock worth $5,152,084 over the last 90 days. 5.30% of the stock is owned by insiders.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.